Steroids and Churg-Strauss syndrome

Lancet

Volumn 352, Issue 9121, 1998, Pages 32-33

  Churg, A ^a   Churg, J ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEUKOTRIENE RECEPTOR BLOCKING AGENT; STEROID; ZAFIRLUKAST;

ARTICLE; ASTHMA; CHURG STRAUSS SYNDROME; EOSINOPHIL; HUMAN; INHALATIONAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STEROID THERAPY;

EID: 0032482649     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)79511-8     Document Type: Article

References (5)

1. 4 receptor antagonist in subjects with bronchial asthma. Am J Respir Crit Care Med 1995; 150: 618-23.
2. 2 Suissa S, Dennis R, Enrst P, Sheehy O, Wood-Dauphinee S. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild to moderate asthma. Ann Intern Med 1997; 126: 177-83.
3. 3 Wechsler ME, Garpestad E, Flier SR, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA 1998; 279: 455-57.
4. 4 Churg A, Brallas M, Cronin SR, Churg J. Formes-frustes of Churg-Strauss syndrome. Chest 1995; 108: 320-23.
5. 5 Terasaki F, Hayashi T, Hiorota Y, et al. Evolution to dilated cardiomyopathy from acute eosinophilic pancarditis in Churg-Strauss syndrome. Heart Vessels 1998; 12: 43-48.